Study confirms early elevated HIV infection risk in some Step Study participants

May 7, 2012

A long-term follow-up analysis of participants in the Step Study, an international HIV-vaccine trial, has confirmed that certain subgroups of male study participants were at higher risk of becoming infected after receiving the experimental vaccine compared to those who received a placebo. The vaccine used in the study did not contain the HIV virus, but it did contain HIV genes which were delivered to cells using a vector that employed a type of cold virus known as adenovirus serotype 5 (Ad5).

Of the 1,836 men examined in this study, 172 became infected with HIV. Within 18 months of enrollment or one year after the last vaccination, men who had neutralizing antibodies to Ad5 or who were uncircumcised, or both, had a two- to four-fold increased risk of acquiring an , according to findings published in the May 4 online edition issue of the .

However, the study also found that the waned after about 18 months to be equal to that of volunteers who received a placebo.

Why this association occurred, what the were and why the risk of infection lessened with time are unknown and require more study, according to Ann Duerr, M.D., a member of the Vaccine and Infectious Disease Division of Fred Hutchinson Cancer Research Center, who led the data analysis.

"There seems to be some kind of biologic phenomena that affects infection risk," she said.

The current study indicated that self-reported , such as unprotected sex, did not differ significantly between the vaccine and placebo arms of the Step trial.

The research also confirmed there was no elevated risk of infection in vaccinated men who were circumcised and who were Ad 5 seronegative (men who had no neutralizing antibodies to the adenovirus vector used in the vaccine). An earlier interim analysis of the Step Study data, done after immunizations in the vaccine trial were halted in 2007, also detected this relationship between Ad5 sero-status and vaccine-associated HIV risk. Today, only men who are circumcised and Ad5 seronegative are eligible to receive experimental HIV vaccines that use the adenovirus serotype 5 as a biological delivery mechanism.

Duerr said scientists need a better understanding of what happened biologically to men who became infected, before those who are uncircumcised or seropositive for Ad 5 are enrolled in future vaccine trials in which the adenovirus serotype 5 vector is used.

Ad 5 is used as a vector because it elicits a strong immune response by CD8 T cells. These cytotoxic T lymphocytes are thought to be responsible for controlling HIV infection.

In the current study, researchers analyzed data from male Step who enrolled in a trial that provided follow-up for up to four years after they enrolled in the Step study, or until Dec. 31, 2009, whichever came first.

The Step Study enrolled 3,000 male and female volunteers in North and South America, the Caribbean and Australia between 2004 and 2007. Injections in the study were halted in September 2007 after researchers detected a lack of effectiveness by the vaccine to prevent HIV acquisition or reduce HIV viral load in infected participants, and a higher-than-expected number of HIV infections in certain subgroups of vaccinees.

Explore further: Another potential obstacle to developing an HIV vaccine

More information: "Extended follow‐up confirms early vaccine‐enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step study)." Journal of Infectious Disease.

Related Stories

Another potential obstacle to developing an HIV vaccine

December 27, 2011
A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work.

Recommended for you

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

National roll-out of PrEP HIV prevention drug would be cost-effective

October 18, 2017
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, ...

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.